Japan's KM Biologics sees overseas demand for newly approved monkeypox vaccine
03/08/2022 10:42
TOKYO, Aug 3 (Reuters) - Japanese pharmaceuticals company KM
Biologics Co has already seen overseas interest in its monkeypox
vaccine which was recently approved by domestic regulators.
KM Biologics, a unit of candy maker Meiji Holdings Co
22.69.T , has had "several inquiries from overseas" a company
official told Reuters on Wednesday, declining to comment on any
export plan for the shot.
Japan's health ministry on Tuesday approved the company's
freeze-dried smallpox vaccine LC16 KMB for use against
monkeypox, after an experts panel recommended the move last
week.
Japan has had only two confirmed cases of monkeypox during
the current global outbreak. urn:newsml:reuters.com:*:nL5N2XF1XF
Based in the southern prefecture of Kumamoto, KM Biologics
mainly produces vaccines for humans and veterinary use. It has
an inactivated COVID-19 shot currently in development.
(Reporting by Rocky Swift; editing by Jason Neely)
((rocky.swift@thomsonreuters.com;))